NetScientific: refinanced and focused on enhancing value

0
27
  • NetScientific expects no change to timing of PDS Biotech trial data
NetScientific PLC -

Quick facts: NetScientific PLC

Follow

View company profile

NetScientific PLC is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

21 Oct 2021

() noted that the temporary suspension by portfolio company () of patient recruitment for one of their clinical studies is not expected to affect the overall timing of clinical data.

PDS issued a statement announcing that the Phase 2 clinical trial led by the National Cancer Institute (NCI), evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers, had paused recruitment due to an issue that is not specific to the trial itself.

The issue is unrelated to any safety or efficacy concerns with the triple combination, NetScientific said, and it is anticipated that it will be determined in a timely manner with trial recruitment to then resume immediately.

PDS chief medical officer Dr Lauren Wood said: “We know from the interim data that this combination has the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options.

Read more

05 Oct 2021

NetScientific PLC (AIM:NSCI, FRA:NTK1) said investee company PDS Biotechnology Corporation (NASDAQ:PDSB) has completed enrolment of the first stage of its phase II head and neck cancer clinical trial.

The checkpoint inhibitor naive arm of its VERSATILE-002 study will treat people with recurrent and/or metastatic human papillomavirus (HPV16) form of the disease.

Read more

30 Sep 2021

A City broker has raised its valuation for shares in NetScientific PLC (AIM:NSCI, FRA:NTK1), saying the potential of its investment portfolio still isn’t being fully understood or recognised by the market.

It was a topic touched upon in Wednesday’s interim figures: “The board remains of the view that the market significantly undervalues the group, with current price below fair value, but without taking into account growth opportunities.”

Read more

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

NetScientific says results mark ‘end of turnaround period, which has been…

NetScientific PLC (AIM:NSCI, FRA:NTK1) (AIM:NSCI, FRA:NTK1) chief executive, Dr Ilian Iliev joins Proactive to discuss their interim results results and statement.

The results for the six months ended June 30 showed the loss for the period was almost GBP1.5mln, reflecting the investments in…

3 weeks, 2 days ago

5 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here